Encouraging updates arise from COVID-19 fluvoxamine trial sparked by U.Va. neuroscience research
By Samuel Opuni | January 4, 2021In comparing Fluvoxamine with a placebo, researchers found that of the 80 participants that received Fluvoxamine, none of them became seriously ill during the trial. Of the patients that received the placebo, six patients became seriously ill and four were hospitalized.